Eclipse plans port-access TMR trial:
This article was originally published in Clinica
Eclipse Surgical Technologies is planning a trial of minimally-invasive laser heart revascularisation, following approval from the FDA. Transmyocardial revascularisation (TMR) uses a laser to drill holes in the heart of patients with angina. Until now Eclipse had performed the procedure through a standard surgical chest incision. The development of a steerable fibreoptic laser catheter will allow the procedure to be performed via a 2-4 inch mini-thoracotomy.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.